Sharp Therapeutics Announces Private Placement of up to US$3.0 Million in Unsecured Convertible Notes

Feb 2, 2026 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – February 2, 2026) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”) is pleased to announce the terms of a proposed non-brokered...

Sharp Therapeutics Appoints Co-Founder Of National Gaucher Foundation And Clinical Researcher Robin Ely, M.D., To Advisory Board

Jan 27, 2026 | Press Releases

PITTSBURGH and TORONTO, Jan. 27, 2026 (GLOBE NEWSWIRE) — Sharp Therapeutics Corp. (“Sharp” or the “Company”) (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeutics for genetic diseases, announced...

Sharp Therapeutics Provides Update on Non-Brokered Private Placement and Grant of Options

Dec 19, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – December 19, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”), is pleased to announce that the non-brokered private...

Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update

Nov 26, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – November 26, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”), announces the release of its condensed interim...

Sharp Therapeutics Arranges Non-Brokered Private Placement

Oct 14, 2025 | Press Releases

Pittsburgh, Pennsylvania and Toronto, Ontario–(Newsfile Corp. – October 14, 2025) – Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) (“Sharp” or the “Company”), is pleased to announce that it is arranging a non-brokered...

Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025

Oct 8, 2025 | Press Releases

PITTSBURGH, Pa. and TORONTO, Oct. 08, 2025 (GLOBE NEWSWIRE) — Sharp Therapeutics Corp. (“Sharp” or the “Company”) (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeutics for genetic diseases, today...